News

Inhalation treatment that uses either nitric oxide or Ventavis (iloprost) is equally effective in managing lingering high lung blood pressure after surgery for chronic thromboembolic pulmonary hypertension (CTEPH). A comparison of the two treatments — published in the journal General Thoracic and Cardiovascular Surgery under the title, “A prospective, randomized study…

Although subcutaneous infusion of Remodulin (treprostinil) is an effective treatment for patients with severe pulmonary arterial hypertension (PAH), it can have undesired effects such as pain at the infusion site. But a study reports that speeding up Remodulin administration, and combining it with injection-site pain management, is an easily tolerated option that may help patients better…

Gilead Sciences reported that selonsertib (also known as GS-4997), an investigational treatment for pulmonary arterial hypertension (PAH), did not achieve the primary endpoint in an analysis of ARROW, a Phase 2 clinical trial (NCT02234141) evaluating the drug’s efficacy, safety and tolerability. The company also reported top-line data from two other…

A team of researchers at Columbia University Medical Center and New York Presbyterian Hospital advise patients with pulmonary hypertension no to become pregnant, based on the case of a 28-year-old woman who was diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), or group 4 pulmonary hypertension, during her pregnancy.

Pregnancy can be a trigger for pulmonary arterial hypertension (PAH) in women with a genetic predisposition to the disease, according to a case study published in the journal Pulmonary Circulation. In the study, “Pregnancy As A Possible Trigger For Heritable Pulmonary Arterial Hypertension,” researchers detail the development of aggressive PAH during…

For the first time, people affected by a host of different diseases, mainly conditions affecting the heart, lungs, kidneys, and liver, met with members of the European parliament to brainstorm ways to efficiently solve issues regarding organ donation and transplant. Healthcare experts, patients, and their families were at the Oct. 18 meeting,…

Bayer will present new data from two different studies of Adempas (riociguat) for pulmonary arterial hypertension (PAH) at the American College of Chest Physicians (CHEST) 2016 Annual Meeting Oct. 22-26 in Los Angeles. One of the presentations will be held during the Late-Breaking Abstracts session of the meeting. Bayer will also…

The Pulmonary Hypertension Association (PHA) is planning a series of events for November, Pulmonary Hypertension Awareness Month, including a daylong focus on chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) that results from blood clots in the lungs. Events planned for CTEPH Awareness Day, Nov. 15, include promoting information about the two…

Patients with pulmonary arterial hypertension (PAH) have higher than usual blood levels of S1P, a molecule that promotes worsening disease, according to a study published in the journal Pulmonary Circulation. The researchers, working in a rat PAH model, also found that blocking this protein improved pulmonary arterial structure and cardiac function, suggesting…

Tyvaso (treprostinil sodium), a drug approved for enhancing exercise capacity in patients with pulmonary arterial hypertension (PAH), was reported in a recent study to be well tolerated and safe in routine clinical use. The study, “An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension,” was published…

A specific gene known as CYP2C44, more active in women with pulmonary hypertension (PH) than in men, may be a key factor in protecting them from more severe forms of the disease, according to results of a study performed with animal models. More women are diagnosed with pulmonary arterial hypertension…

Elsevier  announced that it is expanding its work with the American College of Chest Physicians (CHEST) to provide CHEST members with detailed and interactive eLearning programs that address their specialities, including pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Elsevier is a provider of scientific, technical and medical information products, and the…